AVANIR to Present at the Piper Jaffray Health Care Conference

ALISO VIEJO, Calif., November 25, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2nd at 2:30 p.m. Eastern time (11:30 a.m. Pacific time) at the New York Palace Hotel in New York. The Piper Jaffray Health Care Conference provides the opportunity for companies to participate in interactive presentations with institutional investors, analysts, and money managers. For more information visit www.piperjaffray.com.

A live audio webcast of the presentation will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the Piper Jaffray Health Care Conference will be available on the Company's website for 30 days.

About AVANIR

AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website:
http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0

AVANIR Investor Contacts
Eric Benevich
Brenna Mullen
949-389-6700
ir@avanir.com

Nov 25, 2009